JP2008543813A5 - - Google Patents

Download PDF

Info

Publication number
JP2008543813A5
JP2008543813A5 JP2008516325A JP2008516325A JP2008543813A5 JP 2008543813 A5 JP2008543813 A5 JP 2008543813A5 JP 2008516325 A JP2008516325 A JP 2008516325A JP 2008516325 A JP2008516325 A JP 2008516325A JP 2008543813 A5 JP2008543813 A5 JP 2008543813A5
Authority
JP
Japan
Prior art keywords
compound according
prevention
treatment
nervous system
central nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008516325A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008543813A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2006/063249 external-priority patent/WO2006134150A1/en
Publication of JP2008543813A publication Critical patent/JP2008543813A/ja
Publication of JP2008543813A5 publication Critical patent/JP2008543813A5/ja
Withdrawn legal-status Critical Current

Links

JP2008516325A 2005-06-17 2006-06-15 5−ht6−受容体阻害剤としてのベンゾフラニル誘導体 Withdrawn JP2008543813A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0501383 2005-06-17
US70652305P 2005-08-09 2005-08-09
PCT/EP2006/063249 WO2006134150A1 (en) 2005-06-17 2006-06-15 Benzofuranyl derivatives as 5-ht6-receptor inhibitors

Publications (2)

Publication Number Publication Date
JP2008543813A JP2008543813A (ja) 2008-12-04
JP2008543813A5 true JP2008543813A5 (enExample) 2009-07-23

Family

ID=36659956

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008516325A Withdrawn JP2008543813A (ja) 2005-06-17 2006-06-15 5−ht6−受容体阻害剤としてのベンゾフラニル誘導体

Country Status (18)

Country Link
US (1) US7582767B2 (enExample)
EP (1) EP1896460B1 (enExample)
JP (1) JP2008543813A (enExample)
KR (1) KR20080017482A (enExample)
CN (1) CN101193885B (enExample)
AU (1) AU2006259082B2 (enExample)
BR (1) BRPI0612746A2 (enExample)
CA (1) CA2610383A1 (enExample)
DE (1) DE602006008002D1 (enExample)
DK (1) DK1896460T3 (enExample)
EA (1) EA015671B1 (enExample)
ES (1) ES2330145T3 (enExample)
IL (1) IL187575A (enExample)
MX (1) MX2007015988A (enExample)
NO (1) NO20080354L (enExample)
NZ (1) NZ563510A (enExample)
WO (1) WO2006134150A1 (enExample)
ZA (1) ZA200710468B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0303480D0 (sv) * 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
CN103880797B (zh) * 2014-03-26 2015-12-02 沈阳大学 苯并呋喃类化合物及其医药用途
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020212395A1 (en) 2019-04-16 2020-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
US20250283174A1 (en) 2022-05-16 2025-09-11 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
DE69930308T2 (de) 1998-12-11 2006-11-30 Virginia Commonwealth University Selektive 5-ht 6-rezeptor-liganden
KR20090019894A (ko) 2001-06-11 2009-02-25 바이오비트럼 에이비(피유비엘) 치환 술폰아미드 화합물, cns 장애, 비만 및 ⅱ 형 당뇨병 치료용 약제로서의 이들의 사용 방법
RS44204A (sr) * 2001-11-22 2007-06-04 Biovitrum Ab., Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1
US7943639B2 (en) * 2002-06-20 2011-05-17 Proximagen Limited Compounds
NZ552282A (en) 2002-06-20 2008-07-31 Biovitrum Ab Publ New compounds useful for the treatment of obesity, type II diabetes and CNS disorders
SE0303480D0 (sv) * 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes

Similar Documents

Publication Publication Date Title
JP2020183410A5 (enExample)
JP2004531516A5 (enExample)
JP2010535252A5 (enExample)
RU2005135958A (ru) Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5, 8, 14-триазатетрацикло[10.3.1.02,11.04,9]-гексадека-2( 11 ), 3,5,7,9-пентаена
EP1988898A2 (en) Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
JP2008531714A (ja) 不安障害の治療用及び/又は予防用の医薬組成物
JP2013545730A5 (enExample)
JP2006503850A5 (enExample)
JP2006143751A5 (enExample)
JP2010511701A5 (enExample)
JP2020514316A5 (enExample)
JP2008539268A5 (enExample)
JP2011516417A5 (enExample)
WO2007050726A3 (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
JP2020512337A5 (enExample)
KR20120101588A (ko) 탄산탈수효소 억제제 및 추가적인 활성제의 조합에 의한 폐쇄 수면 무호흡 증후군의 치료
JP2006518731A5 (enExample)
JP2008539267A5 (enExample)
JP2003519228A5 (enExample)
EP2129400A2 (en) Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
JP2012531402A5 (enExample)
JP2002535370A5 (enExample)
ES2426008T5 (es) Tratamiento de síntomas de la enfermedad de Parkinson con ligandos del receptor de histamina H3 de alquilaminas no imidazólicas
EP1621198A3 (en) Substituted carbostyril derivatives as 5-HT 1A receptor subtype agonists
JP2008543813A5 (enExample)